Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease in Europe
TOKYO, Jan 11, 2023 ̵ […]
ป้ายกำกับ: alzheimer’s
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
TOKYO, Jan 9, 2023 – […]
Eisai’s Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer’s Disease, in Thailand
TOKYO, Nov 4, 2022 – […]
Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022
TOKYO, Jul 26, 2022 ̵ […]
U.S. FDA Accepts and Grants Priority Review for Eisai’s Biologics License Application of Lecanemab
TOKYO, Jul 6, 2022 – […]
Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM
Cambridge, MA, Jan 28, 20 […]
Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
TOKYO, Jan 19, 2022 ̵ […]
Eisai: New Phase 3 Data Show Positive Correlation Between ADUHELM Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
TOKYO, Nov 12, 2021 ̵ […]
Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference
TOKYO and CAMBRIDGE, Mass […]
Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study
TOKYO, Nov 4, 2021 – […]
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
TOKYO, Jul 30, 2021 ̵ […]
Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
TOKYO, Jul 27, 2021 ̵ […]
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer’s Disease and Dementia at AAIC 2021
TOKYO, Jul 21, 2021 ̵ […]
Biogen and Eisai launch initiatives to help patients with Alzheimer’s disease access ADUHELM
Cambridge, MA, Jun 8, 202 […]
FDA grants accelerated approval for ADUHELM as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
TOKYO, Jun 8, 2021 – […]
Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer’s Disease by Dian-Tu
TOKYO, Mar 16, 2021 ̵ […]
